Clinical Research Directory
Browse clinical research sites, groups, and studies.
Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty
Sponsor: Chiayi Christian Hospital
Summary
Venous thromboembolism is a serious complication after total hip replacement (THR) and total knee replacement (TKR). Previous studies have reported the incidence of both asymptomatic and symptomatic deep vein thrombosis (DVT) after TKR were higher in Taiwan than other countries in Asia. Therefore, the usage of prophylactic antithrombotics should be considered. The efficacy and safety of Xarelto (Rivaroxaban) for preventing venous thromboembolism has been proved. However, there is a lack of study using prospective design to evaluate the efficacy and safety of Xarelto after THR and TKR for Taiwanese. In this study, the investigators use a randomized controlled trial design comparing the incidence of DVT, pulmonary embolism, and complications between intervention and control groups.
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2023-02-01
Completion Date
2025-09-21
Last Updated
2026-04-24
Healthy Volunteers
No
Conditions
Interventions
Rivaroxaban 10 MG
Patients are randomly divided into two groups. One group receives no prophylaxis with an anticoagulant, the other one receives Rivaroxaban. The dosage of Rivaroxaban is 10 mg given orally once daily starting on the day of the surgery and continuing the following 13 days.
Locations (1)
Ditmanson Medical Foundation Chiayi Christian Hospital
Chiayi City, Taiwan, Taiwan